GIBRALTAR INDUSTRIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GIBRALTAR INDUSTRIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.05B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.39B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.34B | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $265.20M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $296.79M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $255.18M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $215.40M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $226.03M | Feb 25, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $258.11M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $274.57M | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $247.63M | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $206.61M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $231.84M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $272.73M | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $265.74M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $237.67M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $282.09M | Feb 21, 2017 |
| FY2016 | Sep 30, 2015 | $304.99M | Feb 21, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $305.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $301.41M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $281.85M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $318.69M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $290.01M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $62.43M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $78.50M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $65.56M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $49.86M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $57.43M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($44.39M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $137.34M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $110.53M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $82.41M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $75.63M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | ($8.55M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $33.76M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $27.29M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $12.06M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $14.36M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.75M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $139.67M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $120.57M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $130.10M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $96.99M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $22.72M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $40.94M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $30.75M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $12.78M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $20.23M | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.70M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $2.90M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $2.20M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $900.0K | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $60.0K | Feb 21, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.44M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $155.73M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $158.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $188.59M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $184.72M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $149.15M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $139.09M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $128.23M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $143.45M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $161.10M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $174.26M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $218.48M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $102.69M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $23.07M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $89.10M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $129.94M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $97.55M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $70.07M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $123.99M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.41M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.37M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $13.88M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $20.14M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $17.71M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $13.07M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $8.78M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $10.37M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $11.40M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $10.78M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.42B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.26B | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | $1.21B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.21B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.21B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $984.45M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $1.06B | Feb 25, 2021 |
| FY2018 | Jan 1, 2018 | $991.57M | Feb 27, 2019 |
| FY2019 | Dec 31, 2017 | $991.39M | Feb 28, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $950.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.05B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $915.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $822.10M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $825.26M | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | $743.81M | Feb 21, 2024 |
| FY2022 | Dec 31, 2019 | $673.96M | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | $596.69M | Feb 23, 2022 |
| FY2018 | Jan 1, 2018 | $531.99M | Feb 27, 2019 |
| FY2020 | Dec 31, 2017 | $531.72M | Feb 25, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $415.03M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $323.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $329.15M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $512.36M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $510.94M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $514.28M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $307.36M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $301.58M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $321.07M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $304.03M | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $831.46M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $875.85M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $738.51M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $627.98M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $545.57M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $469.94M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $405.67M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $339.00M | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | $274.84M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $274.56M | Feb 27, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.72M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $269.48M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $99.43M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $17.61M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $12.85M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $32.05M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $191.36M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $297.01M | Feb 28, 2020 |
| FY2019 | Dec 31, 2017 | $222.28M | Feb 28, 2020 |
| FY2019 | Dec 31, 2016 | $170.18M | Feb 28, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2023 | Dec 31, 2023 | $0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2022 | $88.76M | Feb 22, 2023 |
| FY2022 | Dec 31, 2021 | $23.78M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $85.64M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $210.40M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $210.02M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $209.64M | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 2 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 2 | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Feb 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Feb 27, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 34.31M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 34.22M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 34.06M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 33.80M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 33.57M | Feb 23, 2022 |
| FY2018 | Dec 31, 2018 | 32.89M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | 32.33M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 32.09M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | 31.78M | Feb 21, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2009 | $1.50M | Feb 25, 2011 |
| FY2010 | Dec 31, 2008 | $5.99M | Feb 25, 2011 |